GeneDx (WGS) Q1 2026 earnings review
Unit Economics Collapse Derails the Turnaround Story
GeneDx delivered a highly disappointing quarter, abruptly ending its four-quarter streak of adjusted profitability. While YoY volume grew 34%, the unit economics collapsed: exome/genome average reimbursement rate (ARR) plummeted to ~$3,300 from ~$3,750 in the prior quarter. Consequently, revenue declined sequentially from $121.0M in Q4 2025 to $102.3M. Management blamed an unfavorable product mix (higher genome, fewer parental samples), but the damage was severe enough to force a massive $65M cut to the midpoint of their FY26 revenue guidance. The narrative of 2026 being a 'breakout year' has been sharply reversed.
🐂 Bull Case
Exome and genome volumes still grew 34% YoY to 27,488 tests. Demand remains intact, indicating that the core problem lies in monetization, not physician adoption.
Medicaid coverage expanded into Texas, Maine, and Arkansas, giving 4.9 million more patients access to testing, providing a wider funnel for future volume.
🐻 Bear Case
Management slashed FY26 revenue guidance by roughly 12% just one quarter into the year, destroying credibility and implying the mix shift issues are structural, not temporary.
The company swung from an adjusted net income of $5.6M in Q4 2025 to an $8.2M loss this quarter, reversing the operating leverage narrative.
⚖️ Verdict: 🟢🟢
Bearish. A massive guidance cut, shrinking unit economics, and a return to cash burn invalidate the bullish thesis established in 2025. The transition into new markets and products is heavily diluting margins.
Key Themes
Reversing Unit Economics (ARR Collapse)
The most alarming metric is the drop in Exome/Genome Average Reimbursement Rate (ARR), which fell to ~$3,300 from roughly $3,750 in Q4 2025. Management cited a shift toward genome testing (45% of the portfolio) and fewer parental samples. Because genomes cost more to process and fewer parental samples mean lower diagnostic yield and billing opportunities, this mix shift directly suffocated revenue growth despite rising volumes.
Operating Expenses Ballooning
Adjusted total operating expenses rose to $78.1M, representing 76% of revenue. This is a severe deterioration from previous quarters where OpEx was guided to fall as a percentage of sales. The aggressive hiring of sales reps to tackle general pediatrics and the NICU is clashing violently with falling unit economics, driving the company back into the red.
Macro Backdrop: Payer Coverage Expanding
Despite the internal execution missteps, the macro reimbursement environment for genomic testing continues to improve. Expanded Medicaid coverage in Texas, Maine, and Arkansas unlocks approximately 4.9 million covered lives, theoretically reducing denial rates in the long term if GeneDx can successfully navigate the revenue cycle.
Product Innovation: Reflex Testing & rWGS
GeneDx launched a new reflex product that seamlessly upgrades non-diagnostic exomes to genome testing. Additionally, new SeqFirst data proved that rapid genome sequencing (rWGS) as a first-tier test in ICUs reduces time to diagnosis by 50%. These clinical proof points are vital for driving deeper penetration into foundational markets.
Sequential Volume Contraction
While management highlighted 34% YoY volume growth, they failed to prominently address the sequential decline. Exome and genome test results were 27,488 in 26Q1, down from 27,761 in 25Q4. For a hyper-growth company in an expansion phase, a sequential volume decline signals decelerating momentum.
GeneDx Infinity Clinical Utility
The company's proprietary rare disease genomic dataset, GeneDx Infinity, was featured in 18 pieces of pioneering research at the ACMG Annual Meeting. The SAVES-Kids study demonstrated up to $80,000 in healthcare cost savings for children with neurodevelopmental disorders following ExomeDx and GenomeDx testing. This HEOR data is crucial for convincing commercial payers to establish favorable medical policies.
Other KPIs
Reversing. Cash used in operating activities plummeted to a $32.4M outflow, compared to a positive $10.2M generated in the same period last year. Total cash and marketable securities declined by ~$10M sequentially, leaving the company with $171.7M to fund its ongoing cash burn.
Stable YoY, but decelerating sequentially from 71% in 25Q4. The flat YoY performance masks underlying pressure, as the higher mix of genome testing carries inherently higher Cost of Goods Sold (COGS) compared to exome panels.
Guidance
Decelerating abruptly. Management brutally cut the previous guidance of $540-$555M by roughly 12% at the midpoint. The new target implies an acknowledgment that the Q1 unit economic issues (lower ARR, shifting product mix) will persist for the rest of the year.
Decelerating. Lowered from the previous expectation of 33% to 35%. This reflects a tempered outlook on physician adoption rates, potentially related to the slower-than-expected ramp of the general pediatrician sales force.
A sequential step-up from Q1's $102.3M, but heavily depressed compared to original expectations. This indicates that while volume may recover slightly, the ARR compression is capping top-line acceleration.
Highly questionable. Q1 delivered an $8.2M loss, and Q2 guidance calls for a ~$5M loss. Achieving a full-year positive result implies a massive, miraculous swing to >$13M in profits during H2, which looks incredibly difficult given the current margin trajectory.
Key Questions
Path to FY26 Profitability
With an $8.2M adjusted net loss in Q1 and a guide for a $5M loss in Q2, H1 will be roughly $13M in the red. What specific cost levers or revenue inflection points provide confidence that H2 will generate enough profit to make FY26 positive overall?
Parental Sample Mix Shift
You noted lower parental sample mix as a key driver of lower ARR. Is this a temporary fluctuation, or a structural change driven by the move into general pediatrics and the NICU where parental samples might be harder to immediately secure?
Genome Unit Economics
As the portfolio mix shifts heavier towards Genomes (now 45%), how are you adjusting lab automation and COGS to prevent this shift from permanently capping gross margins at 69-70%?
Sales Force Productivity
Given the sequential volume decline in exomes/genomes, are the ~100 new commercial reps ramping slower than expected? How has the timeline for general pediatrician adoption been impacted?